Option Care Health Inc Dossier
Qualitative Analysis
Business overview
Option Care Health, Inc. (NASDAQ: OPCH) is the nation's largest independent provider of home and alternate site infusion services. Operating across all 50 U.S. states with a team of over 8,000 members, including more than 5,000 clinicians, the company provides high-quality, clinically managed infusion therapies to patients with complex acute and chronic conditions. Option Care Health partners with managed care organizations, third-party payers, hospitals, physicians, and biopharmaceutical manufacturers to deliver complex compounded pharmaceuticals and clinical management solutions directly in patients' homes or at its national network of alternate site infusion suites.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing on operational improvements, commercial reinvestment, and sequential rebuilding to address the sharper-than-modeled CID reset tied to the shift of the Stelara patient census and payer-driven reverification friction.
Expected impact: Mitigating the 600 basis point revenue growth headwind and stabilizing the chronic therapy segment margins.
Capitalizing on the high single-digit growth rates in the acute therapy business by expanding hospital-alternative care services and executing strategic initiatives in favorable market dynamics.
Expected impact: Partially offsetting chronic therapy segment challenges and driving sustainable top-line growth.
Executing share repurchases under the expanded program authorized by the Board of Directors, which increased the capacity from $500 million to $1.0 billion.
Expected impact: Supporting per-share financial metrics and returning capital to shareholders.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To strengthen Option Care Health's clinical capabilities, expand its geographic footprint in the Southeast, and reinforce its advanced practitioner model.
Financial impact: Bolstered clinical depth and expanded the regional network, contributing to the Southeast market presence.
Strategic Partnerships
Option Care Health was selected to support the commercial development and efficient launch of Quince's lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in the U.S. (assuming regulatory approval). This leverages Option Care's national network of specialty pharmacies and ambulatory infusion suites.
Terms: Terms not fully disclosed; structured to leverage Option Care's single-provider contracting and scalability.